Nirsevimab

ATI-format individual drug card with NCLEX-focused assessment, safety, teaching, and source attribution.

Back to meds
RespiratoryInfectious DiseasePediatricsneeds review

Nirsevimab

ATI class: RSV monoclonal antibody / Respiratory syncytial virus prevention agent

Action

  • ATI/source-folder candidate for Nirsevimab; verify mechanism against the source table before validation.

Therapeutic use

  • Review under Upper Respiratory Tract Disorders medication safety.

Nursing assessment

  • Assess age, weight, RSV season timing, prior dose history, hypersensitivity history, and current acute illness.
  • Monitor for injection reaction, rash, wheezing, facial swelling, or hypotension after administration.
  • Differentiate prophylaxis from treatment of acute respiratory distress.

Administration

  • Verify route against the order and source table.

Side effects

  • Verify common side effects against the source table.

Adverse effects

  • Injection-site reaction
  • Rash
  • Hypersensitivity
  • Anaphylaxis

Interactions

  • Vaccine schedule coordination may need source-specific review.
  • Other monoclonal antibody or immune therapies require medication reconciliation.

Contraindications

  • See source-specific contraindications and precautions before administration.

Precautions

  • Severe hypersensitivity to nirsevimab or components
  • Acute moderate or severe illness may require deferral review.
  • Pediatric eligibility criteria must be verified.

Client teaching

  • Explain that it helps prevent severe RSV disease and does not treat acute breathing distress.
  • Report wheezing, swelling, hives, or trouble breathing immediately.
  • Continue infection-prevention measures and follow routine care instructions.

Medication outcomes

  • Therapeutic response with no priority adverse effects.

Antidote / rescue

  • No specific antidote is seeded; hold/question unsafe doses and manage toxicity per provider, facility, or poison-control guidance.

NCLEX priority cues

  • Breathing difficulty beats comfort symptoms.
  • Wheezing, facial swelling, or hypotension after administration is an emergency.
  • Prophylaxis does not replace urgent assessment for cyanosis or respiratory distress.

Medication classes

Antivirals

Source attribution

Google Drive source topic: Upper Respiratory Tract Disorders
google-drive
Sentinel pharmacology API reference
sentinel-api
Manual ATI-format NCLEX candidate normalization
manual-seed

Related study cards

Shows the medication class, ATI cues, source references, and connected study cards for this drug.

12 study links
Med classmedication class
Antivirals

Interferes with viral replication; exact target and timing depend on the antiviral.

ATI cuePrecaution
Acute moderate or severe illness may require deferral review.

ATI medication precaution concept.

ATI cueAdverse Effect
Anaphylaxis

ATI medication adverse effect concept.

ATI cueNursing Assessment
Assess age, weight, RSV season timing, prior dose history, hypersensitivity history, and current acute illness.

ATI medication nursing assessment concept.

ATI cueMechanism of Action
ATI/source-folder candidate for Nirsevimab; verify mechanism against the source table before validation.

ATI medication mechanism of action concept.

ATI cueNCLEX Priority Cue
Breathing difficulty beats comfort symptoms.

ATI medication nclex priority cue concept.

ATI cueClient Teaching
Continue infection-prevention measures and follow routine care instructions.

ATI medication client teaching concept.

ATI cueNursing Assessment
Differentiate prophylaxis from treatment of acute respiratory distress.

ATI medication nursing assessment concept.

ATI cueClient Teaching
Explain that it helps prevent severe RSV disease and does not treat acute breathing distress.

ATI medication client teaching concept.

ATI cueAdverse Effect
Hypersensitivity

ATI medication adverse effect concept.

ATI cueAdverse Effect
Injection-site reaction

ATI medication adverse effect concept.

ATI cueNursing Assessment
Monitor for injection reaction, rash, wheezing, facial swelling, or hypotension after administration.

ATI medication nursing assessment concept.